Manganese porphyrin: Phase I data

In a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in about 30 patients, single subcutaneous doses of 3, 12, 30, 45, 60 and 75 mg were well tolerated. Plasma area under the cur...